Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 The Federated Tumor Segmentation (FeTS) Challenge.CoRR.  abs/2105.05874. 2021
2020 NKX3.1 Identifies Prostatic Origin of Dural Metastasis in the Setting of Negative Prostate-Specific Antigen StainNeurohospitalist.  10:314-317. 2020
2019 Inception modules enhance brain tumor segmentationFrontiers in Computational Neuroscience.  13. 2019
2019 Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational studyPLoS Medicine.  16. 2019
2019 Approximate kernel reconstruction for time-varying networksBioData Mining.  12. 2019
2018 Global asymptotic stability in a model of networks 2018
2017 Key rates for the grades and transformation ability of glioma: model simulations and clinical casesJournal of Neuro-Oncology.  133:377-388. 2017
2017 Single cell mathematical model successfully replicates key features of GBM: Go-or-grow is not necessaryPLoS ONE.  12. 2017
2016 Automated Robust Image Segmentation: Level Set Method Using Nonnegative Matrix Factorization with Application to Brain MRIBulletin of Mathematical Biology.  78:1450-1476. 2016
2016 The case for neurological network diseasesJAMA Neurology.  73:261-262. 2016
2016 Computational trials: Unraveling motility phenotypes, progression patterns, and treatment options for glioblastoma multiformePLoS ONE.  11. 2016
2015 ATCT-04RETROSPECTIVE ANALYSIS OF TUMOR TREATING FIELDS (TTFIELDS) IN ADULTS WITH GLIOBLASTOMA: SAFETY PROFILE OF THE OPTUNE™ MEDICAL DEVICE IN PATIENTS WITH IMPLANTED NON-PROGRAMMABLE SHUNTS, PROGRAMMABLE SHUNTS, AND PACEMAKERS/DEFIBRILLATORSNeuro-Oncology.  17:v1.4-v1. 2015
2015 Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomasJournal of Neuro-Oncology.  122:585-593. 2015
2015 Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade gliomaNeuro-Oncology.  17:1275-1283. 2015
2014 Effects of anti-angiogenesis on glioblastoma growth and migration: Model to clinical predictionsPLoS ONE.  9. 2014
2014 Case 212: Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroidsRadiology.  273:940-947. 2014
2014 A Multilayer Grow-or-Go Model for GBM: Effects of Invasive Cells and Anti-Angiogenesis on GrowthBulletin of Mathematical Biology.  76:2306-2333. 2014
2014 The future of neuroscience clinical trials-reply.JAMA Neurology.  71:652-653. 2014
2014 Case 212Radiology.  272:605-607. 2014
2014 Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitroJournal of Neuro-Oncology.  118:61-72. 2014
2014 In replyJAMA Neurology.  71:652-653. 2014
2014 Proper orthogonal decomposition for parameter estimation in oscillating biological networksJournal of Computational and Applied Mathematics.  258:135-150. 2014
2014 Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parametersJournal of Neuro-Oncology.  120:361-370. 2014
2014 The role of Src family kinases in growth and migration of glioma stem cellsInternational Journal of Oncology.  45:302-310. 2014
2014 Tracking of time-varying genomic regulatory networks with a LASSO-Kalman smoother 2014
2013 c-Src and Neural Wiskott-Aldrich Syndrome Protein (N-WASP) Promote Low Oxygen-Induced Accelerated Brain Invasion by GliomasPLoS ONE.  8. 2013
2013 Prognostic Relevance of Cytochrome c Oxidase in Primary Glioblastoma MultiformePLoS ONE.  8. 2013
2013 Network for excellence in neuroscience clinical trials NeuroNEXTJAMA Neurology.  70:1227-1228. 2013
2012 Primary central nervous system angiosarcoma: Two case reportsJournal of Medical Case Reports.  6. 2012
2011 Fractal dimension of the drosophila circadian clock 2011
2011 Pontine ring-enhancing glioblastoma multiforme-like fungal abscessArchives of Neurology.  68:1476-1477. 2011
2011 Gene expression analysis in radiotherapy patients and C57BL/6 mice as a measure of exposure to ionizing radiationRadiation Research.  176:49-61. 2011
2011 Modeling of regulatory networks: Theory and applications in the study of the drosophila circadian clockMethods in Enzymology.  487:39-71. 2011
2010 Dynamics of the drosophila circadian clock: Theoretical anti-jitter network and controlled chaosPLoS ONE.  5. 2010
2010 Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcomeClinical Cancer Research.  16:2890-2898. 2010
2010 A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastomaArchives of Neurology.  67:313-319. 2010
2010 Malignant astrocytomas: A system diseaseArchives of Neurology.  67:353-355. 2010
2010 Bevacizumab is active as a single agent against recurrent malignant gliomas 2010
2010 Apparent widening gap in access to neuro-oncologic care in the United States: Need for actionArchives of Neurology.  67:1137-1139. 2010
2010 Model of the Drosophila Circadian Clock: Loop Regulation and Transcriptional IntegrationBiophysical Journal.  98:738a-739a. 2010
2009 Mathematical model of the Drosophila circadian clock: Loop regulation and transcriptional integrationBiophysical Journal.  97:2399-2408. 2009
2009 Optic neuropathy in patients with glioblastoma receiving bevacizumabNeurology.  73:1924-1926. 2009
2008 Approximation by Cubic Splines Leads to Highly Specific Discovery by MicroarraysOpen Bioinformatics Journal.  2:54-59. 2008
2006 Microarray data analysis: Current practices and future directions 2006
2005 Noise and rank-dependent geometrical filter improves sensitivity of highly specific discovery by microarraysBioinformatics.  21:4255-4262. 2005
2005 Logical networks inferred from highly specific discovery of transcriptionally regulated genes predict protein states in cultured gliomasBiochemical and Biophysical Research Communications.  336:1278-1284. 2005
2005 Microarrays: Applications and pitfallsArchives of Neurology.  62:1669-1672. 2005
2005 Genomic discovery reveals a molecular system for resistance to oxidative and endoplasmic reticulum stress in cultured gliomaArchives of Neurology.  62:233-236. 2005
2004 Mathematical algorithm for discovering states of expression from direct genetic comparison by microarraysNucleic Acids Research.  32:3807-3814. 2004
2003 Genomic expression discovery predicts pathways and opposing functions behind phenotypesJournal of Biological Chemistry.  278:23830-23833. 2003
2002 Darts in the dark cure animal, but not human, brain tumorsArchives of Neurology.  59:721-724. 2002
2002 Mathematical modeling of noise and discovery of genetic expression classes in gliomasOncogene.  21:7164-7174. 2002
2001 Survival in a transgenic model of FALS is independent of iNOS expression [1]Annals of Neurology.  50:273. 2001
2000 Demyelination but no cognitive, motor or behavioral deficits after adenovirus-mediated gene transfer into the brain 2000
2000 Gene transfer into brain parenchyma elicits antitumor effectsCancer Research.  60:1797-1799. 2000
2000 Fiction, reality, and molecular neurologyArchives of Neurology.  57:63-64. 2000
2000 Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesisJournal of Immunology.  164:217-222. 2000
2000 Molecular advances to treat cancer of the brainExpert Opinion on Investigational Drugs.  9:1207-1215. 2000
1999 New molecular strategies to cure brain tumors.Archives of Neurology.  56:449-453. 1999
1999 Paraneoplastic neurological syndromes: Paraneoplastic or neurological?Archives of Neurology.  56:151-152. 1999
1998 Brain tumors in the elderly: Undefeated and gaining groundArchives of Neurology.  55:905-906. 1998
1998 Priming in the brain, an immunologically privileged organ, elicits anti- tumor immunityInternational Journal of Cancer.  75:266-276. 1998
1997 Intensive radiation therapy concurrent with up to 7-week continuous-infusion paclitaxel for locally advanced solid tumors: phase I studies.Seminars in Oncology.  24:S2-81-S2-84. 1997
1996 Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2: A case reportCancer.  77:1544-1550. 1996
1991 Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration 1991
Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge

Chapter

Year Title Altmetric
2013 Intervention and Control of Gene Regulatory Networks: Theoretical Framework and Application to Human Melanoma Gene Regulation.  215-238. 2013
Anti-Angiogenesis, Gene Therapy, and Immunotherapy in Malignant Gliomas
Systems Biology of Glioblastoma Multiforme

Research Overview

  • Mathematical Modeling
    Cancer Biology
    Dynamical Systems
    Network Theory
  • Investigator On

  • NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) Collaborative Agreement  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • A Pilot Study of Voraxaze(glucarpidase) in Patients with Central Nervous System Lymphoma  awarded by Memorial Sloan-Kettering Cancer Center 2019 - 2024
  • Brain Tumor Trials Collaborative Agreement  awarded by NIH - National Institutes of Health/DHHS 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC. 2021 - 2023
  • Private Grant  awarded by AGIOS 2020 - 2022
  • Private Grant  awarded by SUMITOMO DIANIPPON PHARMA ONCOLOGY INC 2018 - 2022
  • Private Grant  awarded by BIOMIMETIX JV LLC 2019 - 2022
  • A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM  awarded by GLOBAL COALITION FOR ADAPTIVE RESEARCH 2020 - 2022
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2022
  • Private Grant  awarded by IN8BIO INC. 2020 - 2022
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2014 - 2021
  • Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients  awarded by Johns Hopkins University 2020 - 2021
  • Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas  awarded by Johns Hopkins University 2020 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2016 - 2021
  • A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM  awarded by Johns Hopkins University 2016 - 2021
  • Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)  awarded by Dana-Farber Cancer Institute 2018 - 2021
  • Phase O/I Study of AMG 232 Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters  awarded by Johns Hopkins University 2020 - 2021
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma  awarded by Johns Hopkins University 2018 - 2021
  • A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide  awarded by Johns Hopkins University 2018 - 2021
  • Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2017 - 2021
  • Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL 101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma  awarded by Johns Hopkins University 2017 - 2021
  • Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations  awarded by Johns Hopkins University 2020 - 2021
  • A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or other Primary Brain Tumor  awarded by Johns Hopkins University 2020 - 2021
  • Individualized Screening Trial of Innovative Glioblastoma Therapy (Insight)  awarded by Dana-Farber Cancer Institute 2019 - 2020
  • Phase I Study of MK-1775 with Radiation and Temozolomide In Patients with Newly Diagnosed Glioblastoma and Evaluation of lntratumoral Drug Distribution in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2013 - 2020
  • Private Grant  awarded by VASCULAR BIOGENICS LTD 2016 - 2020
  • Private Grant  awarded by STEMLINE THERAPEUTICS INC 2014 - 2019
  • Private Grant  awarded by NATIVIS, INC. 2015 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by ORBUS THERAPEUTICS, INC. 2016 - 2018
  • A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)  awarded by Johns Hopkins University 2013 - 2018
  • Private Grant  awarded by ARCHER BIOSCIENCES 2013 - 2018
  • Private Grant  awarded by ABBVIE INC 2015 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma  awarded by Johns Hopkins University 2016 - 2018
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma (ABTC 1401)  awarded by Johns Hopkins University 2015 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2015 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients  awarded by Johns Hopkins University 2014 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Brain Tumor Tissue Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by ARCHER BIOSCIENCES 2014 - 2015
  • A Phase lb Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2010 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2014
  • ACRIN 6684: Phase II Assessment of Tumor Hypoxia in Glioblastoma Using FMISO with PET and MRI (R09-185)  awarded by American College of Radiology 2010 - 2014
  • Private Grant  awarded by EMD SERONO 2009 - 2013
  • Private Grant  awarded by EMD SERONO 2009 - 2013
  • Education And Training

  • Doctor of Philosophy in Mathematics, University of Illinois System : Chicago 2007
  • Doctor of Medicine, 1985
  • American University Beirut, Internship 1986
  • Duke University Medical Center, Residency 1990
  • University of Chicago Hospitals, Residency 1989
  • Memorial Sloan Kettering Cancer Center, Postdoctoral Fellowship 1993
  • Full Name

  • Hassan Fathallah-Shaykh